Revive Therapeutics' experimental COVID treatment fails in late-stage study
06/07/2023 11:36
July 6 (Reuters) - Revive Therapeutics RVV.CD said on Thursday its experimental COVID-19 treatment did not meet the main goal of a late-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta) ((Sriparna.Roy@thomsonreuters.com))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure